Genzyme Genetics Sublicenses Cancer MDx Rights to DxS | GenomeWeb
NEW YORK (GenomeWeb News) – Genzyme Genetics has sublicensed rights for diagnostic testing of epidermal growth factor receptor mutations in non-small cell lung cancer to Manchester, UK-based DxS, the firms announced today.
 
The license grants DxS worldwide rights, except for North America and Hong Kong, to commercialize diagnostic and research products that detect mutations in the kinase domain of the EGFR gene.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.